The assay aims to identify small molecules that can increase the production of functional survival motor neuron protein SMN2, which is deficient in spinal muscular atrophy (SMA). The assay uses a luciferase reporter gene appended after the SMN2 gene to measure the amount of functional SMN2 produced. The assay targets increasing the inclusion of exon 7, which generates functional luciferase enzyme. The assay is proposed as a potential therapy for SMA. Is the molecule effective to this assay?